Given that reducing KIF5B in P301S mice partially alleviates tauopathy, it is plausible to consider targeting KIF5B as a viable therapeutic approach for AD and other tauopathies (Selvarasu et al., 2022). The gene discussed is KIF5B; the disease is tauopathy.